These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22839673)

  • 41. [Combination drug therapy in hypertension].
    Tsukiyama H; Shigemasa T; Ikoma E
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():596-602. PubMed ID: 15171443
    [No Abstract]   [Full Text] [Related]  

  • 42. Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers.
    Siragy HM
    J Hypertens; 2010 Jan; 28(1):2-8. PubMed ID: 19797978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fixed low-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension.
    de Leeuw PW; Kroon AA
    J Hypertens Suppl; 1997 Mar; 15(2):S39-42. PubMed ID: 9218197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy].
    Karpov IuA
    Kardiologiia; 2005; 45(12):87-92. PubMed ID: 16353053
    [No Abstract]   [Full Text] [Related]  

  • 45. [Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy].
    Agabiti-Rosei E
    Drugs; 2003; 63 Spec No 1():19-29. PubMed ID: 12708883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Angiotensin converting enzyme inhibitors and calcium antagonists: a synergistic action for a better prevention of cardiovascular events].
    Boutouyrie P
    Therapie; 2009; 64(4):241-8. PubMed ID: 19804704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Comparative study of spirapril (quadropril) and amlodipine efficacy. Results of randomized trial in patients with mild to moderate arterial hypertension].
    Shal'nova SA; Martsevich SIu; Deev AD; Kutishenko NP; Kukushkin SK; Manoshkina EM; Alimova EV; Semenova IuE; Lebedev AV; Koniakhina IP; Zagrebel'nyĭ AV
    Ter Arkh; 2000; 72(10):86-9. PubMed ID: 11220888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P
    Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence].
    Simonyi G; Ferenci T
    Orv Hetil; 2016 Jan; 157(1):30-4. PubMed ID: 26708684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
    Antza C; Stabouli S; Kotsis V
    Vasc Health Risk Manag; 2016; 12():443-451. PubMed ID: 27895487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Organoprotective effects of the combination of perindopril and amlodipine depending on the renal functional state in patients with arterial hypertension].
    Iskenderov BG; Budagovskaia ZM; Sisina ON
    Klin Med (Mosk); 2013; 91(12):35-40. PubMed ID: 25702428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
    Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
    Schmieder RE
    Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
    Deeks ED
    Am J Cardiovasc Drugs; 2009; 9(6):411-8. PubMed ID: 19929039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The influence of combined therapy with calcium antagonist and angiotensin-converting enzyme inhibitor on the circadian profile of arterial pressure in patients with arterial hypertension in the Far North].
    Zapesochnaia IL; Avtandilov AG
    Klin Med (Mosk); 2014; 92(10):33-40. PubMed ID: 25782319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood pressure reduction and control with fixed-dose combination perindopril/amlodipine: A Pan-Hellenic prospective observational study.
    Manolis A; Grammatikou V; Kallistratos M; Zarifis J; Tsioufis K
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):930-5. PubMed ID: 26297703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of antihypertensive drugs of various pharmacological groups on reaction of arterial pressure under conditions of stree testing. Part II. Value of various strategies of potentiation of systemic vasodilatation].
    Praskurnichiĭ EA; Shevchenko OP; Makarova SV; Zhukova VA; Savel'eva SA
    Kardiologiia; 2008; 48(4):18-24. PubMed ID: 18447835
    [No Abstract]   [Full Text] [Related]  

  • 59. The efficacy and safety of fixed-dose combination of amlodipine/benazepril in Chinese essential hypertensive patients not adequately controlled with benazepril monotherapy: a multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial.
    Yan P; Fan W;
    Clin Exp Hypertens; 2014; 36(4):268-74. PubMed ID: 23859303
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
    Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
    J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.